Johanna E.M. Groener
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johanna E.M. Groener has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Johannes M. F. G. Aerts
Department of Medical Biochemistry and Department of Bio‐organic Synthesis Leiden Institute of Chemistry (LIC) Leiden University Leiden the Netherlands
4 shared publications - Mina Mirzaian
Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, The Netherlands
2 shared publications Aldi Poppema
Department of Medical Biochemistry, Academic Medical Center, Amsterdam, the Netherlands
1 shared publicationB J H M Poorthuis
1 shared publicationBen J.H.M. Poorthuis
Departments of Medical Biochemistry and Internal Medicine
1 shared publication- Ben Jhm Poorthuis
Department of Medical Biochemistry, Academic Medical Centre, PO Box 22660, 1100 DD, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 31 October 2011
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 69
Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
Background: Enzyme replacement therapy is currently the only approved therapy for Fabry disease. From June 2009 on, viral contamination of Genzyme's production facility resulted in a worldwide shortage of agalsidase beta leading to involuntary dose reductions (approved dose 1 mg/kg/eow, reduced dose 0.5 mg/kg/m), or switch to agalsidase alpha (administered dose 0.2 mg/kg/eow). An assessment report from the European Medicines Agency (EMA) raised serious concerns about an increase in adverse events at lower dosages of agalsidase beta. We determined the influence of the shortage on clinical event incidence and the most sensitive biochemical marker (lysoGb3) in Dutch Fabry patients. Methods: The incidence of clinical events per person per year was calculated from start of agalsidase beta treatment until the shortage, and was compared to the incidence of clinical events during the shortage period. In addition, plasma lysoGb3, eGFR, quality of life (SF-36) and brief pain inventory (BPI) questionnaires were analysed. Results: All thirty-five Dutch Fabry patients using agalsidase beta (17 males) were included. Mean clinical event incidence was unchanged: 0.15 events per person per year before versus 0.15 during the shortage (p = 0.68). In total 28 clinical events occurred in 14 patients during 4.6 treatment years, compared to 7 events in 6 patients during the 1.3 year shortage period. eGFR and BPI scores were not significantly altered. Two SF-36 subscales were significantly but minimally reduced in females. In males, lysoGb3 increased with a median of 8.1 nM (range 2.5 - 29.2) after 1 year of shortage (p = 0.001). Increases in lysoGb3 were found in both patients switching to agalsidase alpha and on a reduced agalsidase beta dose. Antibody status, treatment duration or clinical event incidence showed no clear correlation to lysoGb3 increases. Conclusions: No increase in clinical event incidence was found in the adult Dutch Fabry cohort during the agalsidase beta shortage. Increases in lysoGb3, however, suggest recurrence of disease activity.
- 31 October 2011
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 69
Open AccessConsequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
Background: Enzyme replacement therapy is currently the only approved therapy for Fabry disease. From June 2009 on, viral contamination of Genzyme's production facility resulted in a worldwide shortage of agalsidase beta leading to involuntary dose reductions (approved dose 1 mg/kg/eow, reduced dose 0.5 mg/kg/m), or switch to agalsidase alpha (administered dose 0.2 mg/kg/eow). An assessment report from the European Medicines Agency (EMA) raised serious concerns about an increase in adverse events at lower dosages of agalsidase beta. We determined the influence of the shortage on clinical event incidence and the most sensitive biochemical marker (lysoGb3) in Dutch Fabry patients. Methods: The incidence of clinical events per person per year was calculated from start of agalsidase beta treatment until the shortage, and was compared to the incidence of clinical events during the shortage period. In addition, plasma lysoGb3, eGFR, quality of life (SF-36) and brief pain inventory (BPI) questionnaires were analysed. Results: All thirty-five Dutch Fabry patients using agalsidase beta (17 males) were included. Mean clinical event incidence was unchanged: 0.15 events per person per year before versus 0.15 during the shortage (p = 0.68). In total 28 clinical events occurred in 14 patients during 4.6 treatment years, compared to 7 events in 6 patients during the 1.3 year shortage period. eGFR and BPI scores were not significantly altered. Two SF-36 subscales were significantly but minimally reduced in females. In males, lysoGb3 increased with a median of 8.1 nM (range 2.5 - 29.2) after 1 year of shortage (p = 0.001). Increases in lysoGb3 were found in both patients switching to agalsidase alpha and on a reduced agalsidase beta dose. Antibody status, treatment duration or clinical event incidence showed no clear correlation to lysoGb3 increases. Conclusions: No increase in clinical event incidence was found in the adult Dutch Fabry cohort during the agalsidase beta shortage. Increases in lysoGb3, however, suggest recurrence of disease activity.
- 4 March 2011
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 35 (2) , 270-271
Ceramide in Lipid Emulsions Used in Parenteral Nutrition
Parenteral nutrition‐associated liver disease is a prevalent and severe complication of long term parenteral nutrition. We present here for the first time data on the presence of ceramide, a bioactive compound involved in a variety of metabolic processes, in different lipid emulsions used in parenteral nutrition. Further research is needed to determine whether this potential harmful bioactive compound is involved in parenteral nutrition‐associated liver disease.
- 4 March 2011
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 35 (2) , 270-271
Ceramide in Lipid Emulsions Used in Parenteral Nutrition
Parenteral nutrition‐associated liver disease is a prevalent and severe complication of long term parenteral nutrition. We present here for the first time data on the presence of ceramide, a bioactive compound involved in a variety of metabolic processes, in different lipid emulsions used in parenteral nutrition. Further research is needed to determine whether this potential harmful bioactive compound is involved in parenteral nutrition‐associated liver disease.
- Open Access
- 1 April 2007
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 53 (4) , 742-747
HPLC for Simultaneous Quantification of Total Ceramide, Glucosylceramide, and Ceramide Trihexoside Concentrations in Plasma
Background: Simple, reproducible assays are needed for the quantification of sphingolipids, ceramide (Cer), and sphingoid bases. We developed an HPLC method for simultaneous quantification of total plasma concentrations of Cer, glucosylceramide (GlcCer), and ceramide trihexoside (CTH).
- 1 April 2007
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 53 (4) , 742-747
Open AccessHPLC for Simultaneous Quantification of Total Ceramide, Glucosylceramide, and Ceramide Trihexoside Concentrations in Plasma
Background: Simple, reproducible assays are needed for the quantification of sphingolipids, ceramide (Cer), and sphingoid bases. We developed an HPLC method for simultaneous quantification of total plasma concentrations of Cer, glucosylceramide (GlcCer), and ceramide trihexoside (CTH).
- 1 October 2003
- Published by Wiley in Pigment Cell Research
- Vol. 16 (5) , 585
SP-18 Inhibition of glycolipid synthesis reduces melanin production in cultured human melanocytes
- 1 October 2003
- Published by Wiley in Pigment Cell Research
- Vol. 16 (5) , 585
SP-18 Inhibition of glycolipid synthesis reduces melanin production in cultured human melanocytes